Advaxis Inc., of Princeton, N.J., was issued three notices of allowance for U.S. Patent applications 12/213,696, 13/254,607 and 11/415,271, related to its cancer immunotherapy platform technology, including composition of matter and methods of use for its immunogenic but non-toxic recombinant tLLO fused to full and partial antigens.

Alzheon Inc., of Lexington, Mass., received a notice of allowance for U.S. Patent application No. 11/871,639, "Methods, Compounds, Compositions and Vehicles for Delivering 3-Amino-1-Propanesulfonic Acid," for its lead therapeutic candidate ALZ-801. ALZ-801 is in a pivotal phase II/III study in Alzheimer's disease patients positive for ε4 allele of the apolipoprotein E.

Anaptysbio Inc., of San Diego, was issued U.S. Patent No. 8,685,897 covering a method of antibody humanization using somatic hypermutation. Leveraging its SHM-XEL platform, the method generates high-potency, humanized therapeutic antibodies using minimal non-human sequence content.

Auspex Pharmaceuticals Inc., of La Jolla, Calif., was issued U.S. Patent No. 8,680,123 and No. 8,383,823, related to the method of treatment, prevention or amelioration of fibrotic conditions such as idiopathic pulmonary fibrosis with SD-560, and the composition of matter for the same product, respectively. SD-560 is the company's deuterium-containing form of pirfenidone drug candidate.

Cytomedix Inc., of Gaithersburg, Md., was issued a notice of allowance for U.S. Patent application 12/966,401 with claims covering methods of use of ALDH bright cells in the treatment of neurological damage arising from an ischemic stroke.

Eagle Pharmaceuticals Inc., of Woodcliff Lake, N.J., was issued U.S. Patent No. 8,685,460 for the treatment of heat stroke with Eagle's dantrolene sodium for injectable suspension. Eagle's dantrolene formulation for the treatment of exertional heat stroke was designated an orphan drug by the FDA Sept. 25, 2012.

Epizyme Inc., of Cambridge, Mass., was issued U.S. Patent No. 8,691,507, "Inhibitors of Human EZH2 and Methods of Use Thereof," relating to the identification of patients carrying EZH2 oncogenic mutations as candidates for treatment with EZH2 inhibitors. EZH2 is a histone methyltransferase that can become oncogenic due to genetic alterations and cause non-Hodgkin lymphoma and solid tumors.

Fate Therapeutics Inc., of San Diego, was issued U.S. Patent No. 8,691,573, "Stem Cell Cultures," related to a class of small-molecule inhibitors of Rho-associated kinase, which are part of the therapeutic application of human induced pluripotent stem cells.

Protelica Inc., of Hayward, Calif., was issued U.S. Patent No. 8,680,019, related to the composition of matter of its bioinformatic-based library, which includes more than 25 billion unique fibronectin-based sequences, called Pronectins.